Literature DB >> 12648984

Hodgkin's lymphoma.

Lynny Yung1, David Linch.   

Abstract

Hodgkin's lymphoma was first described in 1832, but the nature of the pathognomic Reed-Sternberg cell, on which diagnosis of the disease is based, has only been elucidated in the past few years. Radiotherapy has been used to treat localised disease since the 1940s, and in the 1960s, effective combination chemotherapy regimens were introduced for anatomically advanced disease. The past three decades have witnessed continued improvement in outcome to such an extent that Hodgkin's lymphoma is now one of the most curable of all non-cutaneous malignancies. With improved survival and extended follow-up, relevance of treatment-induced late effects has become apparent, and modern therapeutic strategies must fully account for these effects. We review the pathology of Hodgkin's lymphoma, and its clinical presentation, investigation, present management, and natural history, including late effects of treatment.

Entities:  

Mesh:

Year:  2003        PMID: 12648984     DOI: 10.1016/S0140-6736(03)12777-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

1.  Occurrence of minimal change nephrotic syndrome in classical Hodgkin lymphoma is closely related to the induction of c-mip in Hodgkin-Reed Sternberg cells and podocytes.

Authors:  Vincent Audard; Shao-yu Zhang; Christiane Copie-Bergman; Catherine Rucker-Martin; Virginie Ory; Marina Candelier; Maryse Baia; Philippe Lang; André Pawlak; Djillali Sahali
Journal:  Blood       Date:  2010-03-03       Impact factor: 22.113

2.  Using haplotype analysis to elucidate significant associations between genes and Hodgkin lymphoma.

Authors:  Anthony M D'Amelio; Claudia Monroy; Randa El-Zein; Carol J Etzel
Journal:  Leuk Res       Date:  2012-08-14       Impact factor: 3.156

Review 3.  Hodgkin's lymphoma presents as an inguinal abscess: a case report and literature review.

Authors:  Muwaffaq Mezeil Telfah
Journal:  BMJ Case Rep       Date:  2012-09-21

4.  Clinical Features and Prognostic Factors of Hodgkin's Lymphoma: A Single Center Experience.

Authors:  Saadettin Kılıçkap; Ibrahim Barışta; Sükran Ulger; Ismail Celik; Uğur Selek; Ferah Yıldız; Ayşe Kars; Yavuz Ozışık; Gülten Tekuzman
Journal:  Balkan Med J       Date:  2013-06-01       Impact factor: 2.021

5.  Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

Authors:  Barbara Savoldo; Cliona M Rooney; Antonio Di Stasi; Hinrich Abken; Andreas Hombach; Aaron E Foster; Lan Zhang; Helen E Heslop; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2007-05-16       Impact factor: 22.113

6.  Rule-based induction method for haplotype comparison and identification of candidate disease loci.

Authors:  Sirkku Karinen; Silva Saarinen; Rainer Lehtonen; Pasi Rastas; Pia Vahteristo; Lauri A Aaltonen; Sampsa Hautaniemi
Journal:  Genome Med       Date:  2012-03-19       Impact factor: 11.117

7.  The long-term effects of chemo radiotherapy on oral health and dental development in childhood cancer.

Authors:  Sh Najafi; Z Tohidastakrad; J Momenbeitollahi
Journal:  J Dent (Tehran)       Date:  2011-03-31

8.  Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma.

Authors:  Christiane Silke Tudor; Heiko Bruns; Christoph Daniel; Luitpold Valentin Distel; Arndt Hartmann; Armin Gerbitz; Maike Julia Buettner
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

9.  Relationship between ambient ultraviolet radiation and Hodgkin lymphoma subtypes in the United States.

Authors:  Emily M Bowen; Ruth M Pfeiffer; Martha S Linet; Wayne T Liu; Dennis D Weisenburger; D Michal Freedman; Elizabeth K Cahoon
Journal:  Br J Cancer       Date:  2016-02-18       Impact factor: 7.640

10.  Primary extranodal head and neck classical Hodgkin lymphoma: A rare clinical case report.

Authors:  Yongzhi Men; Xuemei Sun; Daolin Wei; Ziwei Yu
Journal:  Exp Ther Med       Date:  2016-05-20       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.